argenx SE - Special Call

Core Insights - The company is hosting a series of R&D Spotlight events, with the first focusing on ARGX-119, a MuSK agonist [1][2] - The initiative to revive these events was driven by requests from analysts and investors, reflecting the company's commitment to being science-based and data-driven [2] Company Developments - The timing for spotlighting ARGX-119 is deemed appropriate, as the company has made a go decision for this molecule into CMS [3]